220 related articles for article (PubMed ID: 11915742)
21. Variability in dose intensity of high-dose methotrexate for nonmetastatic osteosarcoma.
Leavey PJ; Mantadakis E; Maale G
Pediatr Hematol Oncol; 2002; 19(7):483-9. PubMed ID: 12217194
[TBL] [Abstract][Full Text] [Related]
22. Acral erythema caused by high-dose methotrexate therapy in patients with osteogenic sarcoma.
Postovsky S; Ben Arush MW
Pediatr Hematol Oncol; 2005 Mar; 22(2):167-73. PubMed ID: 15805003
[TBL] [Abstract][Full Text] [Related]
23. High-dose methotrexate-induced bullous variant of acral erythema.
Hellier I; Bessis D; Sotto A; Margueritte G; Guilhou JJ
Arch Dermatol; 1996 May; 132(5):590-1. PubMed ID: 8624164
[No Abstract] [Full Text] [Related]
24. Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective.
Mahadeo KM; Santizo R; Baker L; Curry JO; Gorlick R; Levy AS
Pediatr Blood Cancer; 2010 Dec; 55(7):1296-9. PubMed ID: 20949591
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of severe side effects of high-dose methotrexate in osteosarcoma].
Umeda T; Takada N; Hodaka E; Endoh F; Ishii T
Gan To Kagaku Ryoho; 1984 Feb; 11(2):285-94. PubMed ID: 6582805
[TBL] [Abstract][Full Text] [Related]
26. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
Chiu TJ; Wang JW; Chen YJ; Tang Y; Huang CH
Chang Gung Med J; 2009; 32(1):72-80. PubMed ID: 19292942
[TBL] [Abstract][Full Text] [Related]
27. [Progress and stagnation in chemotherapy protocols for primary osteosarcoma].
Delépine N; Alkallaf S; Cornille H; Markowska B; Delépine G
Ann Med Interne (Paris); 2003 Feb; 154(1):12-24. PubMed ID: 12746655
[TBL] [Abstract][Full Text] [Related]
28. Transient cerebral dysfunction secondary to high-dose methotrexate.
Walker RW; Allen JC; Rosen G; Caparros B
J Clin Oncol; 1986 Dec; 4(12):1845-50. PubMed ID: 3465876
[TBL] [Abstract][Full Text] [Related]
29. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
[TBL] [Abstract][Full Text] [Related]
30. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
31. Anaphylaxis during the first course of high-dose methotrexate: a case report and literature review.
Pugi A; Benemei S; Vietri M; Tondo A; Calvani AM; Mugelli A; Vannacci A; Lapi F
J Clin Pharm Ther; 2012 Apr; 37(2):245-8. PubMed ID: 21569069
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
[TBL] [Abstract][Full Text] [Related]
33. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.
Mir O; Ropert S; Babinet A; Alexandre J; Larousserie F; Durand JP; Enkaoua E; Anract P; Goldwasser F
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1059-63. PubMed ID: 20155268
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
35. [High-dose methotrexate and cerebral neurotoxicity. Apropos of a case of arachnoiditis].
Brain E; Alexandre J; Minozzi C; Misset JL
Presse Med; 1997 Mar; 26(6):265-8. PubMed ID: 9122123
[TBL] [Abstract][Full Text] [Related]
36. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
37. Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature.
Perez-Verdia A; Angulo F; Hardwicke FL; Nugent KM
Pharmacotherapy; 2005 Sep; 25(9):1271-6. PubMed ID: 16164401
[TBL] [Abstract][Full Text] [Related]
38. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
[TBL] [Abstract][Full Text] [Related]
39. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function.
Hempel L; Misselwitz J; Fleck C; Kentouche K; Leder C; Appenroth D; Rost M; Zintl F
Med Pediatr Oncol; 2003 Jun; 40(6):348-54. PubMed ID: 12692801
[TBL] [Abstract][Full Text] [Related]
40. [Successful treatment with administration of systemic high dose methotrexate and intraarterial carboplatin for osteosarcoma of the skull: a case report].
Kitai R; Sato K; Kodera T; Nakagawa T; Kabuto M; Kobayashi H; Kubota T; Nozaki J
No Shinkei Geka; 1995 Feb; 23(2):157-61. PubMed ID: 7877737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
